
WHAT IS CLAIMED:

1. A compound having the structural Formula (I'):



(I')

or a pharmaceutically acceptable salt thereof, wherein:

X is a bond, $C(R^{14})_2$, O, S, SO, SO_2 or NH;

Y is CR^9 or N, wherein when Y is N, Z is CR11 and V is CR^{10};

V is CR^{10} or N, wherein when V is N, Z is CR11 and Y is CR^9;

Z is CR^{11} or N, wherein when Z is N, V is CR10 and Y is CR^9;

R^1 is a heterocycloalkyl, C_3-C_{12}cycloalkyl, aryl, C_1-C_6alkylaryl or when taken with R^2, and the nitrogen which they are bonded, forms nitrogen-containing ring, wherein the heterocycloalkyl, C_3-C_{12}cycloalkyl, aryl, C_1-C_6alkylaryl or nitrogen-containing ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, oxo, $COOC_1$-C_6alkyl, C_1-C_6alkyl$COOC_1$-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkylC_3-C_6cycloalkyl, aryl, C_1-C_6alkyl, -C_1-C_6alkylOhaloC_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ and C_1-C_6alkyl$N(R^7)(R^8)$;

R^2 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl or C_1-C_6alkylOH or when taken with R^1, and the nitrogen which they are bonded, forms a nitrogen-containing ring, wherein the nitrogen-containing ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, OH, C_1-C_6alkoxy,

C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, oxo, $COOC_1$-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ and C_1-C_6alkyl$N(R^7)(R^8)$;

R^3 is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$, C_1-C_6alkyl$N(R^7)(R^8)$, C_1-C_6alkyl$(OCH_2CH_2)_nN(R^7)(R^8)$ or C_1-C_6alkylOhaloC_1-C_6alkyl or when taken with R^4 forms a C_3-C_6cycloalkyl or C_3-C_6heterocycloalkyl;

R^4 is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$, C_1-C_6alkyl$N(R^7)(R^8)$, C_1-C_6alkyl$(OCH_2CH_2)_nN(R^7)(R^8)$ or C_1-C_6alkylOhaloC_1-C_6alkyl or when taken with R^3 forms a C_3-C_6cycloalkyl or C_3-C_6heterocycloalkyl;

R^5 is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$ or when taken with R^6 forms a C_3-C_6cycloalkyl or C_3-C_6heterocycloalkyl;

R^6 is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$ or when taken with R^5 forms a C_3-C_6cycloalkyl or C_3-C_6heterocycloalkyl;

R^7 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, COC_1-C_6alkyl or $COOC_1$-C_6alkyl;

R^8 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, COC_1-C_6alkyl or $COOC_1$-C_6alkyl;

R^9 is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$;

R^{10} is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$;

R^{11} is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$;

R^{12} is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$;

R^{13} is hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ or C_1-C_6alkyl$N(R^7)(R^8)$;

each occurrence of R^{14} is independently selected from the group consisting of hydrogen, halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, $CON(R^7)(R^8)$, $N(R^7)(R^8)$ and C_1-C_6alkyl$N(R^7)(R^8)$;

n is 1, 2, 3 or 4; and

m is 0, 1 or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is O.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is CH_2.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is O.


5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is SO_2.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is $C(R^{14})_2$, wherein each occurrence of R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C_1-C_6alkoxy and C_1-C_6alkyl.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is $C(R^{14})_2$, wherein each occurrence of R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C_1-C_6alkoxy and C_1-C_6alkyl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is a bond.

9. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:




and

wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylCOOH, COOH, oxo, COOC_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkylC_3-C_6cycloalkyl, aryl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOhaloC_1-C_6alkyl, C_1-C_6alkylOH, CON(R^7)(R^8), N(R^7)(R^8) and C_1-C_6alkylN(R^7)(R^8);

R^7 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl or C_1-C_6alkylOH; and


R^8 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl or C_1-C_6alkylOH.

10. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylOhaloC_1-C_6alkyl, oxo, COOC_1-C_6alkyl, C_1-C_6alkyl, haloC_1-C_6alkyl and C_1-C_6alkylOH.

11. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is:




wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C_1-C_6alkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkylOhaloC_1-C_6alkyl, oxo, COOC_1-C_6alkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, NH_2, and C_1-C_6alkylOH.

12. The compound of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen.

13. The compound of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^1 is taken with R^2 and the nitrogen to which they are bonded, to form a nitrogen-containing ring.

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the nitrogen-containing ring is:



.

15. The compound of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen, C_1-C_6alkylOC_1-C_6alkyl or C_1-C_6alkyl or when taken with R^4 forms a C_3-C_6heterocycloalkyl.

16. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen or C_1-C_6alkyl or when taken with R^4 forms a C_3-C_6heterocycloalkyl.

17. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^5 is hydrogen or C_1-C_6alkyl.

18. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydrogen or C_1-C_6alkyl.

19. The compound of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are independently selected from the group consisting of hydrogen, halogen, OH, C_1-C_6alkylOH, C_1-C_6alkylalkoxy, C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkyl, C_1-C_6alkylOhaloC_1-C_6alkyl, $CON(C_1$-C_6alkyl$)_2$, C_1-C_6alkyl$N(R^7)(R^8)$ and C_1-C_6alkyl$(OCH_2CH_2)_nN(R^7)(R^8)$;

R^7 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, COC_1-C_6alkyl or $COOC_1$-C_6alkyl;

R^8 is hydrogen, C_1-C_6alkylCOOH, COOH, C_3-C_6cycloalkyl, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkylOH, COC_1-C_6alkyl or $COOC_1$-C_6alkyl; and

n is 3.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2, R^{12} and R^{13} are independently selected from the group consisting of hydrogen, halogen, OH, C_1-C_6alkylOH, C_1-C_6alkylalkoxy and C_1-C_6alkylOC_1-C_6alkyl, C_1-C_6alkyl.

21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is $C(R^{14})_2$, R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C_1-C_6alkylOH, C_1-C_6alkylalkoxy, C_1-C_6alkylOC_1-C_6alkyl and C_1-C_6alkyl.

22. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Y is CH.


23. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is CH.

24. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein V is CH.


25. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is N and Y and V are both CH.

26. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein V is N and Y and Z are both CH.


27. A compound selected from the group consisting of:




,











,



















,



















,










,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



\ ,



,


































































































































































,

,

,

,

,

,

,

,

,

,


































- 227 -



,

,

,

,

,

,

,

,

,

,



















































































































































































































































,



,



,



,



,



,



,



,



,



,


















































































































Cl

































































































































,



,



,



,



,


,


,








,








and


;




or a pharmaceutically acceptable salt thereof.

28. A compound selected from the group consisting of



,

,

,

,

,







and


29. A compound selected from the group consisting of





, or a pharmaceutically acceptable salt thereof.

30. A compound having the formula




, or a pharmaceutically acceptable salt thereof.

31. A compound having the formula



, or a pharmaceutically acceptable salt thereof.

32. A compound having the formula



, or a pharmaceutically acceptable salt thereof.

33. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 in the manufacture of a medicament for the treatment of Plasmodium infection, or malaria.

34. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 in the manufacture of a medicament for inhibiting plasmepsin X.

35. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 in the manufacture of a medicament for inhibiting plasmepsin IX.

36. The use of a compound, or pharmaceutically acceptable salt thereof, of claim 1 in the manufacture of a medicament for dual inhibition of plasmepsin IX and plasmepsin X.

37. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

39. Use of a compound of claim 1, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a *Plasmodium* infection, or for treating malaria, wherein the compound of claim 1, or a pharmaceutically acceptable salt thereof, is to be administered together with an effective amount of one or more additional anti-malarial agents.

40. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of malaria by inhibition of plasmepsin X, IX and at least one other mechanism, wherein the compound of claim 1, or pharmaceutically acceptable salt thereof, is to be administered together with an effective amount of one additional anti-malarial agent, wherein the additional anti-malarial agent acts through a different mechanism than inhibiting plasmepsin IX or plasmepsin X.

41. The compound of claim 1, or pharmaceutically acceptable salt thereof, for use as a medicament.